Fig. 2
From: Preclinical safety and hepatotoxicity evaluation of biomineralized copper sulfide nanoagents
The pharmacokinetics, biodistribution and elimination of LNPs and SNPs. The rats were administered BSA@Cu2−xS NPs of two different sizes by a single-dose intravenous administration (5 mg/kg Cu). A The pharmacokinetic profile of LNPs and SNPs in the blood. B The biodistribution of both NPs in five major organs at different time points up to 168 h (1 week). C Cumulative excretion of LNPs and SNPs into urine and feces. Values are represented as the mean ± SD